Candidemia recurrente y aislamiento de Candida auris resistente a equinocandinas en paciente portador de acceso venoso central de larga duración

Mulet-Bayona, Juan Vicente; Salvador-García, Carme; Tormo-Palop, Nuria; Gimeno-Cardona, Concepción.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 40(6): 334-335, Jun-Jul, 2022. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-206899

Documentos relacionados

  1. Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy.
  2. European confederation of medical mycology quality of clinical candidaemia management score: A review of the points based best practice recommendations.
  3. Critical appraisal beyond clinical guidelines for intraabdominal candidiasis.
  4. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
  5. Whole genome sequencing analysis demonstrates therapy-induced echinocandin resistance in Candida auris isolates.
  6. Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species.
  7. Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.
  8. Recurrent candidemia and isolation of echinocandin-resistant Candida auris in a patient with a long-term central catheter.
  9. Rapid Evolution of Multidrug Resistance in a Candida lusitaniae Infection during Micafungin Monotherapy.
  10. Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?